Posts tagged buy rating
HCW starts Pharming at buy

H.C. Wainwright launched coverage of  Pharming Group NV (AEX:PHARM) with a “buy” rating and €1.50 price target. The stock was recently quoted at €0.45. 

Read More
HCW starts AzurRx at buy

H.C. Wainwright initiated coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and $8 price target. The stock closed at $4.11 on July 24.

Read More
Ladenburg cuts Aradigm price target to $7.50

Ladenburg Thalmann slashed its price target for Aradigm (NASDAQ:ARDM) to $7.50 from $26 but maintained its “buy” rating after the company reported mixed top-line Phase 3 results for Pulmaquin for the treatment of non-cystic fibrosis bronchiectasis (NCF-BE).

Read More
Roth upgrades Cogentix Medical to buy

Roth Capital Partners upgraded Cogentix Medical (NASDQQ:CGNT) to “buy” from “neutral” and raised its price target to $2.20 from $1.25 after the company announced proposed equity financing and debt conversion transactions. The stock closed at $1.20 on Wednesday.

Analyst Chris Lewis writes that the transactions that would transform the company’s capital structure and significantly improve its net cash balance, leaving it much better positioned to maintain its market leadership position versus recent competitive entrants as well as become more opportunistic on the M&A front to add new sources of revenues over time.

Read More
Wainwright starts Nabriva Therapeutics at buy

H.C. Wainwright initiated coverage of Nabriva Therapeutics (NASDAQ:NBRV) with a “buy” rating and $16 price target. The stock closed at $7.92 on Wednesday.

Originally spun-off from Sandoz, Austria-based Nabriva has in-house expertise and broad, wholly-owned IP protection in the development of a novel pleuromutilin class of antibiotics.

Read More
Roth starts Neuralstem at buy

Roth Capital Partners launched coverage of Neuralstem (NASDAQ:CUR) with a “buy” rating and price target of $1.20. The stock closed at 25 cents on Friday.

Analyst Joseph Pantginis writes that Neuralstem has undergone a major restructuring and “we believe new management has righted the ship as it is now focused on small molecule approaches to neurological disorders.” 

Read More
Roth starts Actinium Pharma at buy

Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday.

“We believe it is an opportune time to explore the investment case of Actinium based on the late-stage nature of the lead asset, addressing unmet medical needs, clinical data in hand, and a broad set of upcoming catalysts,” writes analyst Joseph Pantginis.

Read More
Analysts start Tactile Systems at buy, outperform

Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively.

Tactile makes pneumatic compression devices (PCD) to treat lymphedema, along with a chronic venous leg ulcer product. Tactile closed an IPO of 4,120,000 shares at $10 apiece earlier this month. The stock was changing hands at $12.98 at mid-day Monday.

Read More
Roth reinitiates coverage of Pieris Pharma at buy

Roth Capital Partners reinitiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with a “buy” rating and $6 price target. The stock closed at $1.70 on Thursday.

“We believe the company’s anticalin platform has broad potential for the long term and that the multiple partners, broad pipeline and flexibility of the platform provide investors with the potential for multiple catalysts along with partner-based non-dilutive funding,” writes analyst Joseph Pantginis.

Read More
Roth downgrades TearLab to neutral

Roth Capital Partners downgraded TearLab (NASDAQ:TEAR; TSX:TLB) to “neutral” from “buy,” citing sales transition challenges. The stock closed at 83 cents on Wednesday.

Analyst Chris Lewis writes that TearLab’s second quarter year-over-year growth of 9% was the lowest since the first quarter of 2012, prompting the company to once again lower its 2016 outlook.

Read More
Stifel downgrades Keryx to hold

Stifel downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target after the company announced an imminent supply disruption with its Auryxia product. The stock closed at $4.72 on Monday.

Read More
Echelon starts Medical Facilities at buy

Echelon Wealth Partners initiated coverage of Medical Facilities (TSX:DR) with a “buy” rating and one-year price target of $22.50. The stock closed at $21.50 on Monday.

Medical Facilities (MFC) is a physician-owned specialty surgical hospital and ambulatory surgery center owner-operator.

Read More
Maxim downgrades Keryx Biopharmaceuticals to hold

Maxim Group downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target for the stock, which was quoted at $5.16, down $2.20, or 30% in trading Monday afternoon.

The move reflected news that Keryx will now face a manufacturing disruption for at least one quarter and possibly more, writes analyst Jason Kolbert.

Read More
HCW analyst assumes coverage of Capricor

H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Capricor Therapeutics (NASDAQ:CAPR) with a “buy” rating and $13 price target. The stock closed at $4.27 on Tuesday.

Capricor has developed three regenerative medicine platforms. They are cardiosphere-derived cells (CDC) for the treatment of heart failure and cardiac regeneration; natriuretic peptides for heart failure; and exosomes for yet-to-be disclosed indications.

Read More
Rodman starts Catalyst Biosciences at buy

odman & Renshaw initiated coverage of Catalyst Biosciences (NASDAQ:CLIO) with a “buy” rating and a 12-month price target of $3.50. The stock closed at $1.25 on Wednesday.

Using its proprietary protease platform, Catalyst Biosciences is advancing its lead hemostasis programs for hemophilia A and B, as well as its anti- complement programs, which could be applicable across various other disorders, including delayed graft function in kidney transplantation and age-related macular degeneration, a chronic eye disease.

Read More
Roth starts PhaseRx at buy

Roth Capital Partners has initiated coverage of PhaseRx (NASDAQ:PZRX) with a “buy” rating and 12-month price target of $8. The stock closed at $5 on Thursday.

“In our opinion, PhaseRx’s technology platform, combined with promising preclinical results, first mover advantage in the multi-billion dollar i-ERT market opportunity, a number of potential upcoming milestones, and a unique scarcity value, make PhaseRx shares well positioned to perform in the coming 12-to-18 months,” writes analyst Sa’ar Yaniv.

Read More
BTIG starts Entellus Medical at buy

BTIG Research has initiated coverage of Entellus Medical (NASDAQ:ENTL) with a ‘buy” rating and $22 price target. The stock closed at $18.58 on Monday.

“Entellus Medical benefits patients, physicians, and payers by moving balloon sinus dilation (BSD) out of the hospital and into physician offices,” writes analyst Dr. Sean Lavin.

Read More
Roth reinitiates coverage of NeoGenomics at buy

Roth Capital Partners has reinitiated coverage on NeoGenomics with a “buy” rating and target price of $10, following its acquisition of Clarient from GE Healthcare. The stock closed at $8.34 on Tuesday.

“We believe NeoGenomics is on the brink of demonstrating significant sales growth and operating leverage over the next several years as the two companies become fully integrated and realize likely better-than-anticipated revenue and cost synergies,” writes analyst Chris Lewis.

Read More
HCW starts Strongbridge Biopharma at buy

H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday.

“Within the span of two years, Strongbridge has made material progress to strengthen its rare endocrine portfolio and had strategically planted its footing in a Cushing’s syndrome asset with comparatively low clinical and regulatory risk,” writes analyst Andrew Fein.

Read More